Tau in Alzheimer's disease
- Primary identifiers
- 5
- Sponsors tracked
- 5
- Evidence types
- 2 of 3
- Last refreshed
- 2026-07-28 · monthly
MightyRayn panel synthesis
OmniRayn’s reading of this landscape — our interpretation, not a registry fact
The most consequential item in this landscape is a dissociation rather than a drug. Post-hoc analysis of a long-running platform trial shows that the phosphorylated-tau species which respond to amyloid removal are not the ones tracking tangle pathology: MTBR-tau243 and p-tau205 keep rising however much plaque is cleared. That reframes tau from a downstream readout of amyloid into a target with its own clock, and it explains why the registry now shows anti-MTBR antibodies and tau imaging running alongside the amyloid programmes rather than behind them. Read the thinness here as a limit of the record, not the field — several tau-directed candidates in the clinic do not state their mechanism, so this page under-counts what is actually running.
Programs and primary evidence
| Sponsor | Asset | Phase | Mechanism | Primary source |
|---|---|---|---|---|
| Bristol-Myers Squibb | BMS-986446 (TargetTau-1) | 2 | anti-MTBR tau monoclonal antibody |
|
| University of Pennsylvania | [18F]-PI-2620 tau PET | 3 | PET imaging of tau accumulation |
|
| Eli Lilly and Company | P-tau217 test (ANCHOR-AD) | 3 | plasma phosphorylated-tau biomarker for risk stratification |
|
| Washington University School of Medicine | DIAN-TU post-hoc analysis | — | dissociation of soluble p-tau species from tangle pathology |
|
| Axon Neuroscience | AADvac1 | — | active immunotherapy against the microtubule-binding region of tau |
|
Method and limits
- Programs are enumerated from primary registries (ClinicalTrials.gov, PubMed). A program appears here only if a primary record links this target to this indication as a therapeutic hypothesis — associations and risk markers are excluded by design.
- Every claim above carries the identifier it rests on. We report what the record states; we do not assert efficacy, and computational findings are pending wet-lab confirmation.
- Absence is not evidence of absence: unregistered, non-US and stealth-stage programs are not visible to these sources.
- This page refreshes monthly (no net-new primary entity in 330 days). Mechanism classifications are our reading of the public record and may be revised.
Want the analysis behind this landscape?
The public page is the map. The full dossier adds differentiation analysis, kill-tests and the whitespace read for this target — the parts we do not publish.